ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial

Borghaeit, H.*; O'Byrnet, K. J.; Paz-Ares, L.; Ciuleanu, T. -E; Yu, X.; Pluzanski, A.; Nagrial, A.; Havel, L.; Kowalyszyn, R. D.; Valette, C. A.; Brahmer, J. R.; Reck, M.; Ramalingam, S. S.; Zhang, L.; Ntambwe, I.; Rabindran, S. K.; Nathan, F. E.; Balli, D.; Wu, Y. -L.广东省人民医院; 南方医科大学; 中山大学
ESMO Open2023-12DOI: 10.1016/j.esmoop.2023.102065
5阅读
引用收藏
分享

摘要

Background: In CheckMate 227 Part 1, first-line nivolumab plus ipilimumab prolonged overall survival (OS) in patients with metastatic non-small-cell lung cancer (NSCLC) and tumor programmed death-ligand 1 (PD-L1) expression >1% versus chemotherapy. We report results from CheckMate 227 Part 2, which evaluated nivolumab plus chemotherapy versus chemotherapy in patients with metastatic NSCLC regardless of tumor PD-L1 expression.Patients and methods: Seven hundred and fifty -five patients with systemic therapy-naive, stage IV/recurrent NSCLC without EGFR mutations or ALK alterations were randomized 1 : 1 to nivolumab 360 mg every 3 weeks plus chemotherapy or chemotherapy. Primary endpoint was OS with nivolumab plus chemotherapy versus chemotherapy in patients with nonsquamous NSCLC. OS in all randomized patients was a hierarchically tested secondary endpoint.Results: At 19.5 months' minimum follow-up, no significant improvement in OS was seen with nivolumab plus chemotherapy versus chemotherapy in patients with nonsquamous NSCLC [median OS 18.8 versus 15.6 months, hazard ratio (HR) 0.86, 95.62% confidence interval (CI) 0.69-1.08, P = 0.1859]. Descriptive analyses showed OS improvement with nivolumab plus chemotherapy versus chemotherapy in all randomized patients (median OS 18.3 versus 14.7 months, HR 0.81, 95.62% CI 0.67-0.97) and in an exploratory analysis in squamous NSCLC (median OS 18.3 versus 12.0 months, HR 0.69, 95% CI 0.50-0.97). A trend toward improved OS was seen with nivolumab plus chemotherapy versus chemotherapy, regardless of the tumor mutation status of STK11 or TP53, regardless of tumor mutational burden, and in patients with intermediate/poor Lung Immune Prognostic Index scores. Safety with nivolumab plus chemotherapy was consistent with previous reports of first-line settings.Conclusions: CheckMate 227 Part 2 did not meet the primary endpoint of OS with nivolumab plus chemotherapy versus chemotherapy in patients with metastatic nonsquamous NSCLC. Descriptive analyses showed prolonged OS with nivolumab plus chemotherapy in all-randomized and squamous NSCLC populations, suggesting that this combination may benefit patients with untreated metastatic NSCLC.

学科与关键词

关键词
nivolumabchemotherapynonsquamous non-small-cell lung cancerimmunotherapyfirst line
相关
加载中…
  • Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)
    Lu, Shun; Wang, Jie; Cheng, Ying; Mok, Tony; Chang, Jianhua; Zhang, Li; Feng, Jifeng; Tu, Hai-Yan; Wu, Lin; Zhang, Yiping; Luft, Alexander; Zhou, Jian-Ying; Ma, Zhiyong; Lu, You; Hu, Chengping; Shi, Yuankai; Ying, Kejing; Zhong, Hua; Poddubskaya, Elena; Soo, Ross A.; Chia, Yee Hong; Li, Ang; Li, Amy; Wu, Yi-Long*Lung Cancer, 2021, 152: 7-14.被引 35
  • Flat-dose nivolumab (NIVO) as second-line (2L) treatment (tx) in Asian patients (pts) with advanced non-small cell lung cancer (NSCLC): CheckMate 870 long-term results
    Lu, S.; Cheng, Y.; Zhou, J.; Wang, M.; Zhao, J.; Wang, B.; Chen, G.; Feng, J.; Ma, Z.; Wu, L.; Wang, C.; Ma, K.; Zhang, S.; Liang, J.; Song, Y.; Wang, J.; Wu, Y-L.; Li, A.; Huang, Y.; Chang, J.European Lung Cancer Congress (ELCC), ELECTR NETWORK, 2022-03-30 To 2022.
  • First-line PD-1/PD-L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non-squamous non-small cell lung cancer: A Bayesian network meta-analysis of randomized controlled trials
    Zhai, Jinzhao; Lu, Jiangyue; Zhang, Zhibo; Wang, Yuan; Li, Xiaoyan; Zhang, Sujie; Mu, Shuai; Zhi, Xiaoyu; Ge, Xiangwei; Lu, Di; Hu, Yi*; Wang, Jinliang*Cancer Medicine, 2022, 11(10): 2043-2055.被引 4
查看全部 →

发表信息

论文状态
公开发表
期刊
ESMO Open
发表日期
2023-12
卷期
第 8 卷, 第 6 期
页码
102065
DOI
10.1016/j.esmoop.2023.102065
成果收录
SCIE
资助标注
Bristol Myers Squibb; Ono Pharmaceutical Company Ltd.

作者

  • B

    Borghaeit, H. (通讯) (第一作者)

  • O

    O'Byrnet, K. J.

查看全部 19 位作者收起作者
  • P

    Paz-Ares, L.

  • C

    Ciuleanu, T. -E

  • Y

    Yu, X.

    zhejiang canc hosp

  • P

    Pluzanski, A.

  • N

    Nagrial, A.

  • H

    Havel, L.

  • K

    Kowalyszyn, R. D.

  • V

    Valette, C. A.

  • B

    Brahmer, J. R.

  • R

    Reck, M.

  • R

    Ramalingam, S. S.

  • Z

    Zhang, L.

    sun yat sen univ

  • N

    Ntambwe, I.

  • R

    Rabindran, S. K.

  • N

    Nathan, F. E.

  • B

    Balli, D.

  • W

    Wu, Y. -L.

    guangdong prov peoples hosp · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417